Clinical Trials Browser

Phase 2 × pasireotide × Endocrine × Clear all

Prolactin-Producing Pituitary Tumor

NCT01253161 2023-03-06

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Phase 2 Completed

29 enrolled 11 charts

EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Neuroendocrine Tumors

NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Phase 2 Withdrawn

Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

NCT01563354 2021-04-02

LUNA

Phase 2 Completed

124 enrolled 18 charts

Endocrine

Carcinoma, Neuroendocrine

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Phase 2 Terminated

68 enrolled 25 charts

Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT00929669 2017-11-28

LAR

Phase 2 Terminated

2 enrolled 3 charts

Endocrine

Pituitary Neoplasms

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2 Terminated

118 enrolled 11 charts

EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT00088595 2012-06-04

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Phase 2 Completed

45 enrolled 10 charts

Endocrine

Carcinoid Tumor, Serotonin Syndrome

Clinical Trials

A Study of Pasireotide in People With Prolactinoma

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Pasireotide in Hyperinsulinemic Hypoglycemia

LUNA

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

LAR

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors